Hemispherx Biopharma, Inc. (HEB) - Financial and Strategic SWOT Analysis Review

Date: October 4, 2016
Pages: 49
Price:
US$ 125.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: HDDA42B0C29EN
Leaflet:

Download PDF Leaflet

Hemispherx Biopharma, Inc. (HEB) - Financial and Strategic SWOT Analysis Review
Hemispherx Biopharma, Inc. (HEB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Hemispherx Biopharma, Inc. (Hemispherx) is a biopharmaceutical company, which develops, manufactures and commercializes drug therapies for the treatments of viral and immune based chronic disorders. It offers products for the treatment of various diseases such as hepatitis B, hepatitis C, chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME), kidney cancer and metastatic malignant melanoma; multiple sclerosis, hepatitis C, HIV, west Nile virus, and SARS; and Alferon LDO (Low Dose Oral), an oral form of Alferon N Injection for influenza viruses. The company operates production facility in New Brunswick, New Jersey, which is designed to produce Alferon and Ampligen. Hemispherx is headquartered in Pennsylvania, the US.

Hemispherx Biopharma, Inc. Key Recent Developments

Sep 22, 2016: Hemispherx Biopharma Announces Granting of Final Settlement of Derivative and Class Action Case
Aug 15, 2016: Hemispherx Biopharma Announces Financial Results for the Six Months Ended June 30, 2016
Jul 19, 2016: Hemispherx Biopharma Bolsters Manufacturing and Scientific Capabilities Through Key Consulting and Management Appointments
Jul 14, 2016: Hemispherx Outlines Key Elements of Strategic Growth Plan and Commitment to Transparency
Jun 08, 2016: Hemispherx Biopharma Enters into Settlement Agreements Dismissing All Pending Shareholder Derivative Litigation, Resolving Disputes with Insurance Carriers

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
SECTION 1 - ABOUT THE COMPANY

Hemispherx Biopharma, Inc. - Key Facts
Hemispherx Biopharma, Inc. - Key Employees
Hemispherx Biopharma, Inc. - Key Employee Biographies
Hemispherx Biopharma, Inc. - Key Operational Employees
Hemispherx Biopharma, Inc. - Major Products and Services
Hemispherx Biopharma, Inc. - Pharmaceutical Pipeline Products Data
Hemispherx Biopharma, Inc., Pipeline Products by Therapy Area
Hemispherx Biopharma, Inc., Pipeline Products by Development Phase
Hemispherx Biopharma, Inc. - History
Hemispherx Biopharma, Inc. - Company Statement
Hemispherx Biopharma, Inc. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Hemispherx Biopharma, Inc. - Business Description
Hemispherx Biopharma, Inc. - Corporate Strategy
Hemispherx Biopharma, Inc. - SWOT Analysis
SWOT Analysis - Overview
Hemispherx Biopharma, Inc. - Strengths
Strength - Strong Patent Portfolio
Strength - Research and Development Facilities
Strength - Business Agreements
Hemispherx Biopharma, Inc. - Weaknesses
Weakness - Competitive Positioning
Weakness - Lack of Revenue from Marketed Products
Hemispherx Biopharma, Inc. - Opportunities
Opportunity - Rising Healthcare Expenditures in the US
Opportunity - Strategic Partnerships
Opportunity - Orphan Drug Designation: Ampligen
Hemispherx Biopharma, Inc. - Threats
Threat - Competitive Environment
Threat - Intellectual Property Risk
Threat - Reliance on Few Suppliers
Hemispherx Biopharma, Inc. - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Hemispherx Biopharma, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
Hemispherx Biopharma, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016
Hemispherx Biopharma, Inc., Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Sep 22, 2016: Hemispherx Biopharma Announces Granting of Final Settlement of Derivative and Class Action Case
Aug 15, 2016: Hemispherx Biopharma Announces Financial Results for the Six Months Ended June 30, 2016
Jul 19, 2016: Hemispherx Biopharma Bolsters Manufacturing and Scientific Capabilities Through Key Consulting and Management Appointments
Jul 14, 2016: Hemispherx Outlines Key Elements of Strategic Growth Plan and Commitment to Transparency
Jun 08, 2016: Hemispherx Biopharma Enters into Settlement Agreements Dismissing All Pending Shareholder Derivative Litigation, Resolving Disputes with Insurance Carriers
May 16, 2016: Hemispherx Biopharma Announces Financial Results for the Three Months Ended March 31, 2016
Apr 20, 2016: Hemispherx Biopharma Retains Huron Consulting Group to Support Partnering Strategy and Planning for Alferon and Ampligen
Mar 29, 2016: Hemispherx Biopharma Announces Financial Results for the Year Ended December 31, 2015
Feb 22, 2016: Hemispherx Biopharma Management Team: Reflects Company’s Aggressive Commitment to Strategies Designed to Reach Commercial Goals, Preserve Financial Capital, and Increase Stockholder Value
Feb 22, 2016: Hemispherx Biopharma Management Team: Reflects Company’s Aggressive Commitment to Strategies Designed to Reach Commercial Goals, Preserve Financial Capital, and Increase Stockholder Value

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

Hemispherx Biopharma, Inc., Key Facts
Hemispherx Biopharma, Inc., Key Employees
Hemispherx Biopharma, Inc., Key Employee Biographies
Hemispherx Biopharma, Inc., Key Operational Employees
Hemispherx Biopharma, Inc., Major Products and Services
Hemispherx Biopharma, Inc., Number of Pipeline Products by Therapy Area
Hemispherx Biopharma, Inc., Number of Pipeline Products by Development Stage
Hemispherx Biopharma, Inc., Pipeline Products By Therapy Area and Development Phase
Hemispherx Biopharma, Inc., History
Hemispherx Biopharma, Inc., Other Locations
Hemispherx Biopharma, Inc., Subsidiaries
Hemispherx Biopharma, Inc., Key Competitors
Hemispherx Biopharma, Inc., Ratios based on current share price
Hemispherx Biopharma, Inc., Annual Ratios
Hemispherx Biopharma, Inc., Interim Ratios
Hemispherx Biopharma, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
Hemispherx Biopharma, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016
Hemispherx Biopharma, Inc., Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

LIST OF FIGURES

Hemispherx Biopharma, Inc., Pipeline Products by Therapy Area
Hemispherx Biopharma, Inc., Pipeline Products by Development Phase
Hemispherx Biopharma, Inc., Performance Chart (2011 - 2015)
Hemispherx Biopharma, Inc., Ratio Charts
Hemispherx Biopharma, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
Hemispherx Biopharma, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016

COMPANIES MENTIONED

Sarepta Therapeutics, Inc.
Baxter Healthcare Corporation
Avant Immunotherapeutics, Inc
Skip to top


Ask Your Question

Hemispherx Biopharma, Inc. (HEB) - Financial and Strategic SWOT Analysis Review
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: